WAKEFIELD, MA, April 27, 2016-

For first responders and front-line healthcare workers, contracting airborne pathogens during pandemic or outbreak crises is a very real danger. Traditional infection-prevention strategies alone are no longer cutting it in an age where resistant strains are becoming far too common. To improve positive patient outcomes and better ensure the health of first responders, hospital workers and other medical professionals, the healthcare community is increasingly turning to antimicrobial-treated products to act as a second line of defense against some of the most common, and dangerous, strains of bacteria and viruses.

Respiratory masks have been a mainstay to block pathogens from entering airways but, before now, they have never been embedded with antimicrobials that could actually kill those pathogens.Sciessent, the leading provider of antimicrobial solutions, today announced that its antimicrobial technology was used in Nexera Medical’s SpectraShield™ 9500 Surgical Mask, the first product of its kind to be approved by the FDA for protection against bacteria and influenza viruses. The mask, which was approved for continuous use of up to eight hours, was proven to kill 99.99% of test bacteria after one hour of contact and inactivate 99.99% of test influenza viruses (seasonal, pandemic, avian, swine and equine) after five minutes of contact.

Nonwovens Markets subscribers - click here to read the full article.

Not a subscriber?

Try Nonwovens Markets free!